Compare · NNNN vs ORKA
NNNN vs ORKA
Side-by-side comparison of Anbio Biotechnology (NNNN) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NNNN and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.07B, about 6.5x NNNN ($936.7M).
- ORKA has hit the wire 11 times in the past 4 weeks while NNNN has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for NNNN).
- Company
- Anbio Biotechnology
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- $936.7M
- $6.07B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 11
Latest NNNN
- SEC Form F-3ASR filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Zhang Michael W.C
- SEC Form 3 filed by new insider Hsu David H
- SEC Form 6-K filed by Anbio Biotechnology
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris
Latest ORKA
- Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $459,101 worth of shares (5,000 units at $91.82) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Klein Lawrence Otto exercised 75,000 shares at a strike of $7.80 and sold $6,887,484 worth of shares (75,000 units at $91.83) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- SEC Form EFFECT filed by Oruka Therapeutics Inc.
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.